Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 221

Similar articles for PubMed (Select 10389914)


Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C.

J Clin Oncol. 2005 Oct 1;23(28):6854-64.


Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO.

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.


Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.

Chapman PB.

Curr Opin Investig Drugs. 2003 Jun;4(6):710-5. Review.


A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.

Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO.

Vaccine. 2004 Jul 29;22(21-22):2904-9.


Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.

Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, Rome L, Zatloukal P, Coens C, Giaccone G.

Eur J Cancer. 2008 Oct;44(15):2178-84. doi: 10.1016/j.ejca.2008.06.036.


Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.

Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC.

Clin Cancer Res. 1999 Oct;5(10):2773-9.


Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, Mansour E, Haller DG, Manola J, Hanna MG Jr.

J Clin Oncol. 2000 Jan;18(1):148-57.


Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.

J Urol. 2000 Apr;163(4):1124-9.


Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.

Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M, Frei E 3rd.

Biol Blood Marrow Transplant. 2002;8(6):326-33.


Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.

Neninger E, Díaz RM, de la Torre A, Rives R, Díaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Pérez R, Vázquez AM.

Cancer Biol Ther. 2007 Feb;6(2):145-50. Epub 2007 Feb 5.


Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.

Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R.

Ann Oncol. 1999 May;10(5):561-7.


Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, et al.

J Clin Oncol. 1994 May;12(5):1036-44.


Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study.

Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, Akazawa T, Matsumoto M, Seya T, Wada M, Toyoshima K.

Surg Today. 2009;39(3):194-200. doi: 10.1007/s00595-008-3826-3. Epub 2009 Mar 12.


1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients.

Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, Rodríguez JL, Barroso Mdel C, Hernández AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gómez RE, Suárez E, Vazquez AM, Perez R, Macias AE.

Cancer Biol Ther. 2007 Dec;6(12):1847-52. Epub 2007 Sep 8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk